• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline Summary.

作者信息

Konstantinopoulos Panagiotis A, Lacchetti Christina, Annunziata Christina M

机构信息

Dana-Farber Cancer Institute, Boston, MA.

American Society of Clinical Oncology, Alexandria, VA.

出版信息

JCO Oncol Pract. 2020 Aug;16(8):e835-e838. doi: 10.1200/JOP.19.00773. Epub 2020 Feb 19.

DOI:10.1200/JOP.19.00773
PMID:32074015
Abstract
摘要

相似文献

1
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline Summary.上皮性卵巢癌的生殖系和体细胞肿瘤检测：美国临床肿瘤学会指南摘要
JCO Oncol Pract. 2020 Aug;16(8):e835-e838. doi: 10.1200/JOP.19.00773. Epub 2020 Feb 19.
2
status assessment in epithelial ovarian cancer and the challenge of tumor testing.上皮性卵巢癌的病情评估及肿瘤检测面临的挑战
Int J Gynecol Cancer. 2020 Sep;30(9):1465-1466. doi: 10.1136/ijgc-2020-001670. Epub 2020 Aug 4.
3
Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.卵巢癌中胚系和体细胞的同步测序：突变率及其对临床决策的影响。
Gynecol Oncol. 2020 Mar;156(3):517-522. doi: 10.1016/j.ygyno.2019.12.010. Epub 2019 Dec 27.
4
BRCA1/2 germline testing in non-mucinous epithelial ovarian carcinoma: changing international practice and implications for service provision.非黏液性上皮性卵巢癌中的BRCA1/2种系检测：国际实践的变化及对服务提供的影响
Eur J Hum Genet. 2017 Feb;25(2):167-168. doi: 10.1038/ejhg.2016.138. Epub 2016 Oct 19.
5
Population-based testing of non-mucinous epithelial ovarian cancer in Scotland.苏格兰基于人群的非黏液性上皮性卵巢癌检测
BJOG. 2018 Oct;125(11):1459. doi: 10.1111/1471-0528.15174. Epub 2018 May 10.
6
Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.土耳其特拉基亚地区高危 BRCA 相关乳腺癌/卵巢癌个体的遗传筛查结果。
J BUON. 2020 May-Jun;25(3):1337-1347.
7
Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.对每个上皮性卵巢癌患者进行胚系 BRCA1/2 突变检测的指征：系统评价。
Eur J Cancer. 2016 Jul;61:137-45. doi: 10.1016/j.ejca.2016.03.009. Epub 2016 May 19.
8
Identifying disparities in germline and somatic testing for ovarian cancer.识别卵巢癌种系和体细胞检测中的差异。
Gynecol Oncol. 2019 May;153(2):297-303. doi: 10.1016/j.ygyno.2019.03.007. Epub 2019 Mar 16.
9
Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.巴西上皮性卵巢癌患者中BRCA1和BRCA2的种系突变
BMC Cancer. 2016 Dec 3;16(1):934. doi: 10.1186/s12885-016-2966-x.
10
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for genetic testing in epithelial ovarian cancer in the United Kingdom.英国妇科癌症学会/英国妇科病理学会联合共识：在英国进行上皮性卵巢癌的基因检测。
Int J Gynecol Cancer. 2024 Sep 2;34(9):1334-1343. doi: 10.1136/ijgc-2024-005756.

引用本文的文献

1
Evaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical data.上皮性卵巢癌患者中BRCA1/2检测率的评估：从真实世界临床数据中获得的经验教训。
Fam Cancer. 2025 May 5;24(2):43. doi: 10.1007/s10689-025-00467-7.
2
Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid Tumors.实体瘤中体细胞BRCA突变的预测价值及治疗意义
Biomedicines. 2024 Mar 6;12(3):593. doi: 10.3390/biomedicines12030593.
3
Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer.
突变与卵巢癌肿瘤突变负担增加和免疫细胞浸润相关。
Int J Mol Sci. 2023 Sep 18;24(18):14212. doi: 10.3390/ijms241814212.
4
Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts.三个基于人群的队列中 12 个基因的种系突变与卵巢癌风险
Cancer Epidemiol Biomarkers Prev. 2023 Oct 2;32(10):1402-1410. doi: 10.1158/1055-9965.EPI-23-0041.
5
Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!卵巢癌的局部HRD检测？是的，我们可以！
Cancers (Basel). 2022 Dec 21;15(1):43. doi: 10.3390/cancers15010043.
6
Choosing which in-hospital laboratory tests to target for intervention: a scoping review.选择针对干预的院内实验室检测：范围综述。
Clin Chem Lab Med. 2022 Nov 22;61(3):388-401. doi: 10.1515/cclm-2022-0910. Print 2023 Feb 23.
7
Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?级联遗传检测完成障碍：我们如何提高遗传性乳腺癌和卵巢癌综合征检测的采用率？
Fam Cancer. 2023 Apr;22(2):127-133. doi: 10.1007/s10689-022-00316-x. Epub 2022 Oct 8.
8
Real-World Data on Newly Diagnosed -Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database.新诊断的BRCA突变高级别上皮性卵巢癌的真实世界数据：法国国家多中心ESME数据库
Cancers (Basel). 2022 Aug 21;14(16):4040. doi: 10.3390/cancers14164040.
9
Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy.卵巢癌中的下一代测序与分子生物标志物——靶向治疗的机遇
Diagnostics (Basel). 2022 Mar 29;12(4):842. doi: 10.3390/diagnostics12040842.
10
Practice guidelines for tumour testing in ovarian cancer.卵巢癌肿瘤检测实践指南。
J Med Genet. 2022 Aug;59(8):727-736. doi: 10.1136/jmedgenet-2021-108238. Epub 2022 Apr 7.